Rare FNIP1 gene variants lower cardiometabolic disease risk
An Old Blood Test Gains New Meaning
For decades, a routine lipid panel gave doctors two numbers that seemed to matter. One was triglycerides, the fat carried through the blood. The other was high-density lipoprotein cholesterol, often called the good cholesterol. Dividing one by the other produced a ratio that looked unremarkable. That ratio, however, has a quieter meaning. It tracks the body’s energy state, not just its cholesterol balance. The findings were published on 5 August 2026. The method is exome sequencing, the reading of the protein-coding parts of the genome in more than a million people. That reading changes how the ratio is understood.
Cardiometabolic diseases, disorders of the heart and metabolism, share a common biological engine. That engine is altered energy metabolism. The disease family includes coronary artery disease, in which the heart’s arteries narrow, along with obesity, type 2 diabetes, and metabolic-dysfunction-associated steatotic liver disease, a fatty liver disease linked to metabolism. Together, these conditions are the leading cause of death worldwide. Energy metabolism is not the same in every person. Some of its variation is inherited. The inherited part is what a genetic study can hunt for. The hunting ground now includes rare variants that change the proteins encoded by genes.
The researchers treated the ratio of triglycerides to high-density lipoprotein cholesterol as an energy-state biomarker. A biomarker is a measured sign of a biological state. A simple ratio, in other words, carries information about the whole metabolic state.
The scale behind these associations is enormous. Exome sequences came from 1,032,116 people. [1] They were drawn from 11 cohorts on three continents. Some participants lived in America, some in Europe, some in Asia. The data also included genome-wide common variants, some statistically imputed, and detailed health measurements. That combination let the researchers validate the ratio as a marker of energy state. It also set the stage for a genetic search. The search asked whether rare coding variants move the ratio up or down. The answer was a list of genes — and one gene in particular.
When a Protective Mutation Upsets the Old Model
Genetic discovery began with a scan across all protein-coding genes. The scan linked rare protein-coding variants to the TG:HDL ratio. The statistical bar was strict: a P value below 1.04 x 10^-7. A P value is a statistical measure of how easily chance could explain a result. Even so, 59 independent genes emerged. These genes are not scattered at random. They are enriched in the liver and in adipose tissue, the body’s fat stores. Many encode master regulators of energy balance, storage, and metabolism, meaning proteins that control many other genes. Some were already known. Others were new to this disease context. The list itself is a resource for the field.
One gene demanded special attention. That gene is FNIP1, short for folliculin interacting protein 1. Ultra-rare protein-truncating variants in FNIP1 have an allele frequency of only 0.01%. Allele frequency is the share of gene copies that carry the variant. A protein-truncating variant cuts a gene’s protein short and often destroys its function. In this case, the effect is protective. Carriers had a lower TG:HDL ratio. They had less fat in the liver. They had lower blood sugar. Their fat distribution was favorable rather than harmful. Their odds of cardiometabolic disease were about 60% lower. [1] This stands the old model on its head.
FNIP1 is not a random metabolic enzyme. It acts as a suppressor of energy expenditure. It also suppresses mitochondrial metabolism, the part of the cell that burns fuel. The researchers tested that change directly in primary human hepatocytes, which are liver cells taken from humans. Knocking down FNIP1, meaning reducing its activity, induced lipid breakdown. The same knockdown induced lysosomal gene expression. Lysosomes are the cell’s recycling and disposal centers.
Mice told the rest of the story. Researchers combined hepatic knockdown of Fnip1, meaning knockdown in the liver, with its paralogue Fnip2. A paralogue is a related gene born from an ancestral duplication. In separate experiments, they knocked down Flcn, which is an interactor of Fnip1. An interactor is a protein that works with FNIP1. Both manipulations protected mice from weight gain on a high-fat diet. Both reduced liver fat. Both enhanced insulin sensitivity, meaning the body responded better to insulin. The mouse results matched the human genetics. That match gives the FNIP1 finding weight.
Drug Targets Emerge From Rare Variant Maps
The gene list is not only biological. It is pharmacological. Of the 59 independent genes, 23 encode approved or clinical-stage drug targets, meaning drugs already approved or being tested in humans. That is 39%. Many of these genes already sit in the pipelines of drug developers. In this way, rare variant maps build a bridge from human genetics to medicine.
The central character of the story is the FNIP1 pathway. In human cells and in mice, the pathway controls energy expenditure and mitochondrial metabolism. Disrupting it changes how the body handles fat. The result is a favorable metabolic profile. This is more than a biological curiosity. It is a potential therapeutic strategy. The word “potential” is important.
The path from a lipid ratio to a drug target is no longer abstract. It runs through one gene: FNIP1.